- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Vekacia meets primary and secondary endpoints in VKC trial
11 May 2016 • Author: Victoria White, Digital Content Producer
Santen has announced that the Phase III clinical trial of its investigational drug, ciclosporin 1mg/mL eye drops, (proposed trade name Vekacia), has met its primary and key secondary endpoints, demonstrating the investigational drug’s efficacy and tolerability in the treatment of active, severe vernal keratoconjunctivitis (VKC) in paediatric patients.
The trial, Vektis, was a multicentre, randomised, double blind, three parallel-arm, placebo-controlled study in patients aged 4–18 years.
VKC is a severe and recurrent allergic eye condition that mainly affects children (predominantly boys) and young adults, and which results in intense itching photophobia, painful eyes, and potentially even permanent loss of vision. The condition is characterised by severe inflammation of the ocular surface, including the conjunctivae and cornea (keratitis). Currently available anti-allergy pharmacological therapies for VKC have shown to be effective in mild-to-moderate forms of the disease, but they do not target the underlying immune process that initiates and perpetuates the allergic ocular surface inflammation – that requires a more potent agent.
Vekacia contains ciclosporin, an immunomodulator that moderates the allergic response and inflammation associated with VKC. Vekacia has been developed as a sterile, positively charged (i.e. cationic), oil-in-water emulsion. This cationic emulsion – developed using Santen’s proprietary Novasorb technology – optimises the delivery of ciclosporin into the eye by binding with the overall negative charge of the ocular surface. Novasorb increases the length of time that the ciclosporin remains on the ocular surface (residence time), thereby optimising its therapeutic effects.
First drug that targets the ungerlying inflammation
Vekacia has been granted orphan drug status by the European Commission (EC) for the treatment of VKC, and if approved by the European Medicines Agency (EMA) will be the first drug that targets the underlying inflammation that causes VKC signs and symptoms.
Commenting on the results, Shigeo Taniuchi, Head of Santen Europe, said: “With these very encouraging results from Vektis, Vekacia is delivering on its promise to provide an innovative and effective treatment that significantly improves outcomes for children with severe VKC. Our investment in VKC reflects our recognised commitment to eye care and to developing paediatric medicines that protect children’s vision and restore quality of life.”
The company says detailed results will be presented in due course at relevant scientific meetings.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics